Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, discusses recent and upcoming updates in the field of polycythemia vera. Dr Bose highlights the use of ropeginterferon alfa-2b, an agent which has already received approval in Europe, and rusfertide, a hepcidin mimetic shown to reduce the need for phlebotomy. Ropeginterferon alfa-2b approval was based on the results of the Phase II PROUD-PV (NCT01949805) and CONTI-PV (NCT02218047) trials. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.